Financials INVO Bioscience, Inc.

Equities

INVO

US44984F4019

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 21:30:00 24/06/2024 BST 5-day change 1st Jan Change
0.8484 USD +1.00% Intraday chart for INVO Bioscience, Inc. -20.71% -37.16%

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 64.45 33.8 28.78 39.08 5.156 3.341
Enterprise Value (EV) 1 64.63 33.01 19.46 35.52 7.73 11.79
P/E ratio -20.1 x -15.5 x -1.98 x -5.29 x -0.47 x -0.26 x
Yield - - - - - -
Capitalization / Revenue 130 x 22.8 x 27.7 x 9.39 x 6.27 x 1.11 x
EV / Revenue 131 x 22.3 x 18.8 x 8.54 x 9.4 x 3.9 x
EV / EBITDA -58.8 x -19.6 x -3.54 x -6.84 x -0.73 x -1.8 x
EV / FCF -101 x -14.8 x -18.2 x -30.6 x -3.07 x 18.4 x
FCF Yield -0.99% -6.76% -5.5% -3.27% -32.5% 5.44%
Price to Book -23.8 x -9.1 x 5.05 x 5.43 x -5.28 x -0.66 x
Nbr of stocks (in thousands) 240 244 478 587 608 2,475
Reference price 2 268.8 138.4 60.20 66.60 8.476 1.350
Announcement Date 16/04/19 30/03/20 30/03/21 31/03/22 17/04/23 16/04/24
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 0.4944 1.48 1.037 4.16 0.8222 3.021
EBITDA 1 -1.099 -1.684 -5.503 -5.189 -10.55 -6.566
EBIT 1 -1.104 -1.694 -5.515 -5.217 -10.63 -6.767
Operating Margin -223.32% -114.47% -531.67% -125.39% -1,292.45% -224.04%
Earnings before Tax (EBT) 1 -3.076 -2.167 -8.347 -6.65 -10.89 -8.007
Net income 1 -3.076 -2.168 -8.347 -6.655 -10.89 -8.035
Net margin -622.22% -146.43% -804.73% -159.97% -1,324.81% -266%
EPS 2 -13.36 -8.929 -30.41 -12.60 -18.00 -5.131
Free Cash Flow 1 -0.6419 -2.233 -1.071 -1.16 -2.514 0.6415
FCF margin -129.84% -150.84% -103.25% -27.89% -305.75% 21.24%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 16/04/19 30/03/20 30/03/21 31/03/22 17/04/23 16/04/24
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1
Net sales 1 3.048 0.1626 0.1461 0.2353 0.2781 0.348 0.3159 0.9749 1.382 1.576
EBITDA - - - - - - - - - -
EBIT 1 0.5036 -2.701 -2.682 -2.525 -2.718 -2.306 -2.066 -0.8863 -1.508 -0.9464
Operating Margin 16.52% -1,661.09% -1,835.1% -1,073.19% -977.31% -662.71% -654% -90.91% -109.17% -60.04%
Earnings before Tax (EBT) 1 0.1018 -2.774 -2.801 -2.55 -2.765 -2.551 -2.238 -1.247 -1.972 -1.595
Net income 1 -0.1415 -2.774 -2.802 -2.55 -2.767 -2.551 -2.241 -1.248 -1.995 -1.597
Net margin -4.64% -1,706.22% -1,917.02% -1,083.47% -994.84% -732.95% -709.25% -128.06% -144.37% -101.28%
EPS -0.4000 -4.600 -4.600 -4.200 -4.600 -4.000 -3.060 -0.7000 - -
Dividend per Share - - - - - - - - - -
Announcement Date 31/03/22 16/05/22 15/08/22 14/11/22 17/04/23 15/05/23 14/08/23 13/11/23 16/04/24 15/05/24
1USD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 0.18 - - - 2.57 8.45
Net Cash position 1 - 0.78 9.32 3.56 - -
Leverage (Debt/EBITDA) -0.1669 x - - - -0.244 x -1.287 x
Free Cash Flow 1 -0.64 -2.23 -1.07 -1.16 -2.51 0.64
ROE (net income / shareholders' equity) 79.7% 67.3% -823% -102% -344% 18,953%
ROA (Net income/ Total Assets) -132% -82.3% -54.1% -30.5% -91.2% -33.8%
Assets 1 2.326 2.633 15.43 21.85 11.95 23.74
Book Value Per Share 2 -11.30 -15.20 11.90 12.30 -1.610 -2.050
Cash Flow per Share 2 0.8800 5.070 21.00 9.530 0.1500 0.0900
Capex 1 0.02 0.11 0.05 0.42 0.01 0.44
Capex / Sales 3.92% 7.75% 4.75% 9.99% 1.31% 14.72%
Announcement Date 16/04/19 30/03/20 30/03/21 31/03/22 17/04/23 16/04/24
1USD in Million2USD
Estimates
  1. Stock Market
  2. Equities
  3. INVO Stock
  4. Financials INVO Bioscience, Inc.